PV-10 is novel. It is unique.
It doesn't fall into any existing class of agent.
As a result, management classified it as a chemoablative immunotherapeutic, a descriptor they coined. A long name? Sure. Maybe their working on a shorter version.
Are there any other agents in this class called chemoablative immunotherapeutics class? No as far as they know. Perhaps, over time, more compounds or active ingredients will be classified in a similar light.
More importantly, to the discussion of intellectual property, where this is all going, is the chemoablative immunotherapeutic class new? Yes.